The HuPaVir® supplement from ADVENTIA PHARMA , obtained positive results in a study that evaluates its effect on the evolution of infections by the Human Papilloma Virus
Dr. Carmen Pingarrón, Quironsalud San José Hospital; Dr. Alfonso Duque, Hospital Ruber Internacional and Dr. Ana López, Hospital HM Vallés present the positive results of the scientific study of oral HuPaVir® supplementation to promote the clearance of the Human Papilloma Virus. < br> for HuPaVir® shows that it is a well-tolerated oral support that helps the patient's immune system to fight against cervical infection by high-risk Human Papillomavirus.
The Congress of the Spanish Association of Cervical Pathology and Colposcopy, held from November 17, will be the event chosen to present the details of the study of oral HuPaVir® supplementation in patients with Human Papillomavirus infection high-risk.
Human Papillomavirus (HPV) is the most common sexually transmitted disease. According to the WHO, HPV is the cause of practically all cases of cervical cancer, which kills more than 300,000 women every year and for which more than 700,000 new cases are diagnosed annually throughout the world.
The medical team formed by Dr. Carmen Pingarrón from the Quironsalud San José Hospital, Dr. Alfonso Duque from the Ruber Internacional Hospital and Dr. Ana López from the HM Vallés Hospital have carried out a study that assesses the effect of nutritional supplementation with HuPaVir on the evolution of high-risk HPV infections in the cervix.
This study has been carried out in 118 women with high-risk HPV infection in the cervix with and without low-grade lesions with an average age of 36 years, since it is after 35 years when there is a higher incidence of cervical cancer.
In conclusion of medical professionals < / b>, the study results indicate that supplementation with HuPaV ir® represents an oral support that helps the patient's own immune system to fight against the cervical infection by high-risk HPV, accelerating the clearance of the virus, favoring the remission of lesions derived from the infection and preventing its progression. Dr. Carmen Pingarrón, assesses the results as " encouraging " highlighting that | the patients in the group that took HuPaVir® had a clearance or negativization of the virus double with respect to control patients ”.
More information about HuPaVir: https://www.adventiapharma.com/en/gynecology/complement/hupavir.html